Condition: Generalized Myasthenia Gravis · Sponsor: Novartis Pharmaceuticals
A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care (SOC) treatment.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Neuromuscular Research Center | Phoenix, Arizona, United States | Recruiting |
| Honor Health Research Institute | Scottsdale, Arizona, United States | Recruiting |
| Fullerton Neuro and Headache Ctr | Fullerton, California, United States | Recruiting |
| University Of Southern California | Los Angeles, California, United States | Recruiting |
| Univ Cali Irvine ALS Neuromuscular | Orange, California, United States | Recruiting |
| California Pacific Medical Center | Sacramento, California, United States | Recruiting |
| Medstar Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| SFM Clinical Research LLC | Boca Raton, Florida, United States | Recruiting |
| Homestead Assoc In Research Inc | Homestead, Florida, United States | Recruiting |
| Neurology Associates PA | Maitland, Florida, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Recruiting |
| Neurological Services of Orlando PA | Orlando, Florida, United States | Recruiting |
+ 117 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06744920